Published on
May 8, 2025
Generic versions of key diabetic drug in market double in a month
In less than two months after diabetes drug Empagliflozin went off patent, Indian branded generic players have crowded the market with their versions of the product leading to a month-on-month doubling in the number of players and brands flooding the …
Source:
The Economic Times
-
Pending
